试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-07
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
编号:NCT02229981登记状态:入组前撤回企业 / 申办者:RedHill Biopharma Limited
药物 / 成分:ABC294640
登记的停止原因(原文):Study was discontinued due to lack of recruitment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-07
GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis
编号:NCT03202004登记状态:入组前撤回企业 / 申办者:GlaxoSmithKline
药物 / 成分:GSK2894512 1% cream、Vehicle cream
登记的停止原因(原文):The decision not to progress the planned Phase 3 studies is a business decision based on the need to prioritise and focus resources within GSK.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-07
Absorption and Tolerability Studies of an Emulsion Containing the Coconut Oil-derived Glycerol Tridecanoate in Healthy Men
编号:NCT03255889登记状态:入组前撤回企业 / 申办者:National University Hospital, Singapore
药物 / 成分:Glyceryl Tridecanoate、Placebo
登记的停止原因(原文):Expiry of grant funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-06
Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients
编号:NCT01886742登记状态:入组前撤回企业 / 申办者:University of Colorado, Denver
药物 / 成分:Standard Dose Group、Weight Based Group
登记的停止原因(原文):Lack of funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-06
Progesterone in Luteal Phase Deficiency
编号:NCT02950948登记状态:入组前撤回企业 / 申办者:IBSA Institut Biochimique SA
药物 / 成分:Progesterone、Placebo
登记的停止原因(原文):inability to recruit an adequate number of subjects.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-06
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
编号:NCT03130764登记状态:入组前撤回企业 / 申办者:Columbia University
药物 / 成分:Durvalumab、Tremelimumab
登记的停止原因(原文):PI Transferred
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-06
Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis
编号:NCT03245671登记状态:入组前撤回企业 / 申办者:Hospital for Special Surgery, New York
药物 / 成分:Kenalog Injectable Product、Decadron Phosphate, Injectable、Epidural Steroid Injection
登记的停止原因(原文):Unable to address regulatory concerns.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-05
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
编号:NCT02765997登记状态:入组前撤回企业 / 申办者:Masonic Cancer Center, University of Minnesota
药物 / 成分:Unmanipulated UCB、SR-1 UCB
登记的停止原因(原文):IRB Disapproval
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-04
Insulin Modulation of fMRI Connectivity in Healthy Adults
编号:NCT02982551登记状态:入组前撤回企业 / 申办者:University of Pittsburgh
药物 / 成分:Insulin、Taste Task、Magnetic Resonance Imaging、Dextrose
登记的停止原因(原文):Principal Investigator Departed University
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-02
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
编号:NCT00855114登记状态:入组前撤回企业 / 申办者:Masonic Cancer Center, University of Minnesota
药物 / 成分:everolimus、therapeutic conventional surgery
登记的停止原因(原文):Withdrawn due to no accrual
查看官方原始记录 ↗